Spinal cord injuries, which affect over 300,000 individuals in the United States alone, have long posed an insurmountable barrier to complete recovery. The primary obstacle lies in the death of neurons at the injury site and the failure of severed nerve fibers to regenerate and reconnect. The new study, published in the prestigious journal Advanced Healthcare Materials, charts a novel path to overcoming these limitations through the use of 3D-printed organoid scaffolds that simulate the architecture of spinal tissue.

At the core of this breakthrough is a meticulously designed scaffold, produced through high-precision 3D printing. This framework incorporates microscopic channels structured to guide the growth and differentiation of spinal neural progenitor cells (sNPCs). These progenitor cells, which originate from human adult stem cells, possess the extraordinary ability to proliferate and mature into diverse types of neural cells necessary for reconstructing damaged spinal circuits.

The scaffold’s microchannels serve not merely as a physical matrix but as directional conduits that instruct the regrowth of nerve fibers. By controlling the orientation and extension of new axons, the scaffold enforces a biologically relevant pattern of regeneration that aligns with the spinal cord’s natural connectivity. Guebum Han, the first author and a former postdoctoral researcher at the University of Minnesota, elaborates that this system acts akin to a neurobiological “relay,” effectively bypassing lesion sites to restore communication pathways.

The team evaluated the efficacy of their organoid scaffold by implanting it into a rat spinal cord model where the spinal cord was fully severed. The results were compelling: transplanted progenitor cells differentiated efficiently into neurons that extended axons bifurcating in both rostral and caudal directions. This bidirectional growth allowed the newly formed neural networks to establish functional synapses with the host’s existing spinal circuits, a critical step toward restoring motor and sensory function.

Crucially, longitudinal observations demonstrated that the new neural tissue integrated seamlessly over time with the host spinal cord, not eliciting significant immune rejection or scar tissue formation—common hurdles in neural regeneration therapies. The structural compatibility facilitated recovery of locomotor functions in treated rats, attesting to the therapeutic promise of this approach.

Ann Parr, a neurosurgery professor at the University of Minnesota and co-author of the study, highlights the transformational aspect of this research. She notes that regenerative medicine is entering an era where “mini spinal cords” grown ex vivo and fashioned into patient-specific implants could become feasible clinical interventions. The scaffold essentially resurrects the intrinsic regenerative capacity of the spinal cord by providing a conducive environment for cell growth and targeted axonal guidance.

Beyond the biological sophistication, this research introduces a scalable fabrication platform. The convergence of additive manufacturing with stem cell technology allows for customizable scaffolds that can be adapted to different injury geometries and patient-specific conditions. Such flexibility is vital for translating these findings from animal models to human clinical trials, where injury heterogeneity is substantial.

While still in early stages, the implications of these findings extend far beyond spinal cord injury treatment. The integration of 3D printed biomimetic scaffolds with progenitor cell populations may open future avenues in repairing other complex nervous system injuries and degenerative diseases. This convergence exemplifies the promise of interdisciplinary innovation at the nexus of engineering and biology.

The researchers plan to refine the scaffold’s design further, optimizing channel architecture and cell seeding protocols to enhance functional recovery. Parallel efforts will focus on ensuring long-term safety and efficacy, as well as developing good manufacturing practice (GMP)-compliant processes for clinical-grade scaffold production.

Funding from the National Institutes of Health, the State of Minnesota’s Spinal Cord Injury and Traumatic Brain Injury Research Grant Program, and the Spinal Cord Society has been instrumental in propelling this ambitious project. Collaborative expertise spanning mechanical engineering, neurosurgery, neuroscience, and physics has underpinned the robust translational strategy inherent in this work.

In summary, the University of Minnesota team’s advancement offers a beacon of hope for those affected by debilitating spinal cord injuries. By bridging bioengineering precision with stem cell biology, this research redefines regenerative paradigms and sets a new standard for restoring connectivity in damaged neural tissues. The full detailed findings and methodology are accessible through Advanced Healthcare Materials for the scientific community eager to build upon this foundation.

Subject of Research: Spinal cord injury recovery through 3D-printed organoid scaffolds incorporating spinal neural progenitor cells.

Article Title: 3D-Printed Scaffolds Promote Enhanced Spinal Organoid Formation for Use in Spinal Cord Injury

News Publication Date: 25 August 2025

Web References:
https://advanced.onlinelibrary.wiley.com/doi/10.1002/adhm.202404817

References:
The detailed study published in Advanced Healthcare Materials, DOI: 10.1002/adhm.202404817

Image Credits: McAlpine Research Group, University of Minnesota

Keywords: Spinal cord injuries, Organoids, Additive manufacturing, Stem cells, Tissue engineering

The approach addresses a dire need in medical treatment for extensive burns and severe wounds, allowing for the restoration of the skin barrier, which is often essential for survival. Historically, the treatment for large burns involved transplanting a thin epithelial layer from the skin, a process that predominantly utilizes a single type of cell, which unfortunately results in significant scar formation. This method overlooks the complexity of skin structure, comprising two vital layers: the epidermis, which is the outermost layer, and the dermis, which lies beneath it. The dermis is pivotal for skin functionality; it possesses nerve endings, blood vessels, hair follicles, and various other critical structures.

Conventional surgical options that aim to repair tissue damage often lead to additional wounds because the dermis is rarely transplantable due to its complexity. The surgical process of accessing and harvesting dermis to rectify a host’s injury leaves behind a substantial wound, conflicting with the objective of effective healing. Researchers, however, have turned the focus toward generating a new form of skin that does not merely become scar tissue but rather matures into a functioning construct.

Within this innovative framework, the most common cell type present in the dermis, the fibroblast, emerges as a prominent candidate for lab cultivation. Fibroblasts are crucial as they can evolve into more specialized cell types as dictated by the healing needs of the tissue. To aid in this transformation, scientists have designed a scaffold that allows these cells to develop upon tiny, porous beads of gelatin, a synthetic substance reminiscent of the collagen found in human skin. However, practical applications of this scaffolding present immediate challenges, particularly in ensuring stability when directly applied to a wound.

The research team resolved this issue by devising a method that harmonizes gelatin beads with a body-specific gel composed of hyaluronic acid. The coalescence of these two materials is deftly executed through an approach called click chemistry, yielding a unique gel composition that resembles “skin in a syringe.” This gel’s notable feature allows it to transform from a liquid state to a gel-like form when subjected to pressure, facilitating its application via a syringe. Once injected, this technology offers the novel capability of 3D printing with live cells embedded in the gel.

The preliminary animal studies conducted involved 3D-printing small pucks of this innovative material, which were subsequently implanted beneath the skin of live mice. Initial results reveal promising indicators, as researchers observed the survival of the cells and their production of essential substances that contribute to dermal formation. More compelling is the formation of blood vessels within the graft material, a crucial aspect that is vital for the longevity and functionality of transplanted tissues in a living organism.

Blood vessel development is a pivotal consideration not just in skin regeneration but in a multitude of engineered tissue applications. One significant limitation within the current framework of engineered tissues resides in their capacity to sustain themselves, as living structures often lack the necessary vascular systems to transport oxygen and nutrients to cells located deep within. This deficiency imposes strict limitations on the size and complexity that tissue constructs can achieve before central cells succumb to anoxic conditions.

Significantly, the researchers at Linköping University are making strides toward addressing this vascular supply conundrum. In a concomitant publication, they detail an innovative methodology for crafting threads formulated from hydrogels, which consist predominantly of water—up to 98%. These hydrogel threads exhibit remarkable elasticity, enabling manipulation through knots and other physical constructs. Furthermore, they can be shaped into mini-tubes, which hold remarkable potential for facilitating fluid transport or supporting the growth of vasculature cells.

These mini-tubes or perfusable channels develop new vistas for organoid development and blood vessel engineering, representing a forward leap in regenerative medicine. As the research progresses, the implications of such advancements could translate into real-world applications, enhancing the scope and effectiveness of tissue engineering whilst addressing some of the long-standing challenges associated with viability and functional integration in complex tissue systems.

The study, led by Johan Junker and Daniel Aili, also integrates the contributions from distinguished peers in the field, emphasizing the collaborative nature of scientific inquiry. With funding sourced from various prestigious institutions, including the European Research Council and the Swedish Research Council, this research underscores the potential resilience and efficacy of new biomedical platforms in reconstructive surgery and beyond.

Ultimately, the voyage of innovation explored through “skin in a syringe” signifies more than just an academic milestone; it embodies a beacon of hope for countless patients grappling with the debilitating effects of burns and severe skin injuries. The journey of realizing efficient, functional, and aesthetically acceptable skin transplants is manifesting through rigorous research, heralding a transformative era in the landscape of medical treatment and regenerative solutions.

Subject of Research: Regenerative medicine, skin transplantation, 3D printing.

Article Title: Skin in a Syringe: Revolutionizing Burn Treatment and Skin Regeneration.

News Publication Date: 12-Jun-2025.

Web References: http://dx.doi.org/10.1002/adhm.202501430

References: Relevant journal articles published in Advanced Healthcare Materials.

Image Credits: Magnus Johansson/Linköping University.

Keywords

Regenerative medicine, 3D printing, skin transplants, fibroblasts, hydrogel, dermal regeneration, vascularization, tissue engineering.

The research team, led by Professor Oleh Taratula from the College of Pharmacy at OSU, has devised a method utilizing specially engineered nanoparticles, which are minuscule carriers smaller than 100 billionths of a meter. These nanoparticles are designed to transport therapeutic agents efficiently and effectively to targeted areas within the brain, significantly overcoming the challenges posed by the blood-brain barrier.

In their experimental approach, the researchers employed dual peptide-functionalized polymeric nanocarriers aimed specifically at targeting the hypothalamus—a critical region of the brain involved in various essential functions, such as appetite regulation, hormone secretion, and thermoregulation. Previous attempts to deliver therapeutic agents to this part of the brain had been largely hampered by the BBB’s impermeable nature, which is intended to protect the brain from harmful substances.

The research findings, recently published in the prestigious journal Advanced Healthcare Materials, reveal substantial progress in addressing this issue. The novel delivery system was tested on a mouse model, demonstrating that these nanoparticles could not only cross the BBB but also reach the hypothalamus and deliver a drug that inhibits a specific protein linked to inflammation. This capability is particularly vital for addressing neuroinflammation linked to cachexia in cancer patients.

Cachexia is a chronic and life-threatening condition that affects up to 80% of patients with advanced cancer. It is marked by significant loss of weight and muscle mass, which occurs despite adequate nutritional intake. The debilitating effects of cachexia worsen patients’ quality of life, hinder their ability to tolerate treatments, and negatively impact their survival prospects. Understanding the role that inflammation plays in dysregulating metabolism and appetite in these patients is critical for developing effective therapeutic strategies.

The researchers focused on the hypothalamus due to its central role in regulating various bodily functions and maintaining homeostasis. They found that inflammation in the hypothalamus was a primary contributor to disordered appetite and metabolism in cachexia patients. As they progressed with their study, they aimed to not only inhibit the inflammatory response but also restore normal appetite and metabolic control in affected individuals.

One of the key challenges associated with brain-targeted drug delivery is ensuring that therapeutic agents reach the correct destination within the hypothalamus. According to Taratula, the study’s nanocarriers demonstrate dual-targeting capabilities to maximize therapeutic efficacy. Even after overcoming the BBB, the nanocarriers specifically target activated microglia cells, which are essential mediators of inflammation in the brain.

The findings indicate that their engineered nanocarriers can successfully deliver an IRAK4 inhibitor specifically to the hypothalamus in mice with cancer cachexia. This is an unprecedented achievement that showcases the potential of these nanocarriers to alter the treatment landscape for patients suffering from cachexia and related inflammatory conditions.

Upon administering the treatment, the scientists observed notable reductions in key inflammatory markers within the hypothalamus. Furthermore, the results were promising, showing a remarkable 94% increase in food intake among treated subjects along with significant preservation of body weight and muscle mass. These results not only highlight the effectiveness of their approach but also suggest broader applications for treating other conditions characterized by brain inflammation.

Beyond its implications for cancer cachexia, Taratula noted that the ability of their nanoplatform to traverse the blood-brain barrier and specifically target microglial cells opens avenues for innovative treatments for neurological disorders such as Alzheimer’s disease and multiple sclerosis. These conditions, which are often associated with chronic neuroinflammation, could benefit from the targeted delivery of anti-inflammatory therapeutics.

The collaborative research effort included contributions from several other faculty members from the OSU College of Pharmacy and an expert from Endevica Bio. Their work has garnered financial support from multiple esteemed institutions, including the National Cancer Institute of the National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Research Foundation of Korea.

In conclusion, the advancement in nanoparticle technology presented by the OSU team marks a pivotal moment in medical research, paving the way for groundbreaking treatments that could fundamentally change how we approach neurological disorders and cachexia in cancer patients. As the research continues to unfold, the implications of this work promise to drive further exploration into innovative treatment methodologies for conditions that have long posed challenges to effective intervention.

Subject of Research: Animals
Article Title: Blood-Brain Barrier-Penetrating Nanocarriers Enable Microglial-Specific Drug Delivery in Hypothalamic Neuroinflammation
News Publication Date: 3-Apr-2025
Web References: DOI Reference
References: Advanced Healthcare Materials
Image Credits: Tetiana Korzun

Keywords: blood-brain barrier, nanocarriers, inflammation, cancer cachexia, hypothalamus, neurological disorders, anti-inflammatory therapy.